Compare Neurocrine Biosciences Inc (NBIX) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Direxion Daily TSLA Bull 2X Shares trades at $10.4 (market cap $3.97B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.6× Direxion Daily TSLA Bull 2X Shares's market cap, and Direxion Daily TSLA Bull 2X Shares is more actively traded (38,458,237 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| NBIX | TSLL | |
|---|---|---|
Market Cap | $14.36B | $3.97B |
Volume | 1,237,180 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $23.03 |
52-Week Low | $123.10 | $6.74 |
Typical Hold Time | 23 Days | 15 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
TSLL, a leveraged ETF tracking Tesla, trades at $10.01, down 1.38% amid neutral technical signals. Moving averages suggest a bullish trend, but RSI indicates overbought conditions. The ETF lacks traditional financial ratios due to its structure, and recent news highlights its volatility tied to Tesla's Cybercab event.
Outlook hinges on Tesla's performance, offering amplified gains but high risk from daily rebalancing. Investors face significant volatility and potential decay, requiring careful risk management given the leveraged nature and dependence on Tesla's stock movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
